Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
2.190
+0.060 (2.82%)
Oct 19, 2026, 10:52 AM EDT - Market open
Zentalis Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
106
Market Cap
207.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 67.43M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Protalix BioTherapeutics | 80.62M |
| Keros Therapeutics | 15.01M |
| Alector | 13.86M |
| Pyxis Oncology | 11.04M |
| Camp4 Therapeutics | 4.22M |
| Sol-Gel Technologies | 1.80M |
| Lyell Immunopharma | 27.00K |
ZNTL News
- 16 hours ago - Zentalis announces first OS data from DENALI part 1b study - TheFly
- 16 hours ago - Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract - GlobeNewsWire
- 14 days ago - Zentalis assumed at Outperform from Market Perform at Leerink - TheFly
- 17 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Zentalis initiated with an Outperform at William Blair - TheFly
- 4 weeks ago - Zentalis Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 weeks ago - Zentalis Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 6 weeks ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire